AmyPore

Description: AmyPore develops AmyP53, an AI-driven drug targeting Alzheimer’s & Parkinson’s, pioneering a new therapeutic class.

Country: France

Based in: Septèmes-les-vallons

Founded: 2018

Funding Stage: Series A/B

Tags: ['Biotechnology', 'Health Care', 'Pharmaceutical']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.